1.1.1.178: 3-hydroxy-2-methylbutyryl-CoA dehydrogenase
This is an abbreviated version!
For detailed information about 3-hydroxy-2-methylbutyryl-CoA dehydrogenase, go to the full flat file.
Word Map on EC 1.1.1.178
-
1.1.1.178
-
l-3-hydroxyacyl-coa
-
2-methyl-3-hydroxybutyric
-
hyperinsulinism
-
tiglylglycine
-
hydroxyacyl-coas
-
choreoathetosis
-
medicine
-
lchad
-
kcnj11
-
2-methylacetoacetate
- 1.1.1.178
- l-3-hydroxyacyl-coa
-
2-methyl-3-hydroxybutyric
- hyperinsulinism
-
tiglylglycine
-
hydroxyacyl-coas
-
choreoathetosis
- medicine
- lchad
-
kcnj11
- 2-methylacetoacetate
Reaction
Synonyms
17beta-HSD10, 17beta-hydroxysteroid dehydrogenase type 10, 2-methyl-3-hydroxy-butyryl CoA dehydrogenase, 2-methyl-3-hydroxybutyryl coenzyme A dehydrogenase, 2-methyl-3-hydroxybutyryl-CoA dehydrogenase, 3-hydroxy-2-methylbutyryl-CoA dehydrogenase, 3-hydroxyacyl-CoA dehydrogenase type II, dehydrogenase, 2-methyl-3-hydroxybutyryl coenzyme A, HADII, HSD10, MHBD, SCHAD, short chain 3-hydroxyacyl-CoA dehydrogenase, short-chain L-3-hydroxy-2-methylacyl-CoA dehydrogenase, type II 3-hydroxyacyl-CoA dehydrogenase
ECTree
Advanced search results
Application
Application on EC 1.1.1.178 - 3-hydroxy-2-methylbutyryl-CoA dehydrogenase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
medicine
-
used for coupled enzyme assay to detect 3-oxothiolase deficiency in L-isoleucine degrading pathway
medicine
-
important in brain development and aging, SCHAD deficiency is an inherited defect in mitochondrial fatty acid oxidation, reported cases of SCHAD deficiency are actually due to a deficiency of HAD, abnormal levels may contribute to the pathogenesis of some neural disorders, potential target for intervention in Alzheimer's disease, Parkinson's disease, and an X-linked mental retardation
medicine
-
MHBD deficiency is a X-linked inborn error in the metabolism of isoleucine. Impairment of energy metabolism seems to play a role in the pathogenesis of MHBD deficiency. Males are more severely affected than females by MHBD deficiency. Male patients with MHBD deficiency before 10 months of age show neurodegeneration, while female carriers show a variety of symptoms (borderline learning difficulties to psychomotor and speech delay)
medicine
mutation p.D86G c.257A>G in exon 3 was diagnosed in one child with a very severe neonatal presentation, absent neurological development and death from progressive hypertrophic cardiomyopathy at the age of 7 months. MHBD activity in fibroblasts was only partially reduced to approximately 30% of normal. Mutation p.Q165H c.495A>C in exon 5 was diagnosed in a boy who presented with pre- and postnatal failure to thrive but normal cognitive and motor development. Neurological examination in this boy and two affected relatives has been entirely normal up to the present age of 8 years. There is no measurable MHBD activity in fibroblasts, molecular studies identified hemizygosity for the mutation. There is no correlation between enzyme activity and clinical presentation. HSD10 is essential for structural and functional integrity of mitochondria independently of its enzymatic activity. Impairment of this function in neural cells causes apoptotic cell death whilst the enzymatic activity of HSD10 is not required for cell survival
medicine
mutant loses most or all catalytic functions, and the males with this mutation have a severe clinical phenotype. The mutation eliminates several hydrogen bonds and reduces the van der Waals interaction between HSD10 subunits. The resulting disruption of protein structure impairs some if not all of the catalytic and non-enzymatic functions of HSD10. Eight patients with the R130C mutation show an average 2-methyl-3-hydroxybutyryl-CoA dehydrogenase activity of only 6% of the normal control level